Forest Laboratories announces publication in the lancet of pivotal Phase III Hypertension trial of the fxed-dose combination of Nebivolol/Valsa

02-06-2014 Business Wire HealthComments (0)

Forest LaboratoriesPharmaceuticalUSA

Forest Laboratories (NYSE:FRX) today announced the publication of data from its pivotal Phase III Study of an Investigational Fixed-Dose Combination (FDC) of nebivolol and valsartan in the May 30, 2014 issue of The Lancet. In the study, the combination of nebivolol and valsartan met its primary and key secondary endpoints, demonstrating statistically significant reductions from baseline in diastolic and systolic blood pressure vs. both nebivolol alone and valsar

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top